---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-24-000027"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:44:19.892016+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q2 net loss $24.6M; pemvidutide MASH Phase 2b topline due Q1 2025

## Summary
- Cash, cash equivalents and short-term investments totaled $164.9M as of June 30, 2024.
- Net loss for Q2 2024 was $24.6M ($0.35 per share) vs. $16.1M ($0.32 per share) in Q2 2023.
- Phase 2b IMPACT trial of pemvidutide in MASH enrollment progressing; topline data expected Q1 2025.
- End-of-Phase 2 FDA meeting for obesity program expected late Q3 2024 to discuss Phase 3 design.
- Phase 2 MOMENTUM obesity trial showed up to 15.6% weight loss at 48 weeks and class-leading lean mass preservation.

## SEC filing metadata
- accession: 0001326190-24-000027
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000027/0001326190-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000027/alt-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-24-000027
- JSON: https://secwatch.observer/filing/0001326190-24-000027.json
- Plain text: https://secwatch.observer/filing/0001326190-24-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.